BridgeDPI: A Novel Graph Neural Network for Predicting Drug-Protein
Interactions
- URL: http://arxiv.org/abs/2101.12547v1
- Date: Fri, 29 Jan 2021 12:53:39 GMT
- Title: BridgeDPI: A Novel Graph Neural Network for Predicting Drug-Protein
Interactions
- Authors: Yifan Wu, Min Gao, Min Zeng, Feiyang Chen, Min Li and Jie Zhang
- Abstract summary: We propose a novel deep learning framework, namely BridgeDPI.
It introduces a class of nodes named hyper-nodes, which bridge different proteins/drugs to work as PPAs and DDAs.
In three real-world datasets, we demonstrate that BridgeDPI outperforms state-of-the-art methods.
- Score: 18.242888464394575
- License: http://arxiv.org/licenses/nonexclusive-distrib/1.0/
- Abstract: Motivation: Exploring drug-protein interactions (DPIs) work as a pivotal step
in drug discovery. The fast expansion of available biological data enables
computational methods effectively assist in experimental methods. Among them,
deep learning methods extract features only from basic characteristics, such as
protein sequences, molecule structures. Others achieve significant improvement
by learning from not only sequences/molecules but the protein-protein and
drug-drug associations (PPAs and DDAs). The PPAs and DDAs are generally
obtained by using computational methods. However, existing computational
methods have some limitations, resulting in low-quality PPAs and DDAs that
hamper the prediction performance. Therefore, we hope to develop a novel
supervised learning method to learn the PPAs and DDAs effectively and thereby
improve the prediction performance of the specific task of DPI. Results: In
this research, we propose a novel deep learning framework, namely BridgeDPI.
BridgeDPI introduces a class of nodes named hyper-nodes, which bridge different
proteins/drugs to work as PPAs and DDAs. The hyper-nodes can be supervised
learned for the specific task of DPI since the whole process is an end-to-end
learning. Consequently, such a model would improve prediction performance of
DPI. In three real-world datasets, we further demonstrate that BridgeDPI
outperforms state-of-the-art methods. Moreover, ablation studies verify the
effectiveness of the hyper-nodes. Last, in an independent verification,
BridgeDPI explores the candidate bindings among COVID-19's proteins and various
antiviral drugs. And the predictive results accord with the statement of the
World Health Organization and Food and Drug Administration, showing the
validity and reliability of BridgeDPI.
Related papers
- ADEP: A Novel Approach Based on Discriminator-Enhanced Encoder-Decoder Architecture for Accurate Prediction of Adverse Effects in Polypharmacy [0.0]
We introduce ADEP, a novel approach integrating a discriminator and an encoder-decoder model to address data sparsity and enhance feature extraction.
ADEP employs a three-part model, including multiple classification methods, to predict adverse effects in polypharmacy.
arXiv Detail & Related papers (2024-05-31T18:20:17Z) - Regressor-free Molecule Generation to Support Drug Response Prediction [83.25894107956735]
Conditional generation based on the target IC50 score can obtain a more effective sampling space.
Regressor-free guidance combines a diffusion model's score estimation with a regression controller model's gradient based on number labels.
arXiv Detail & Related papers (2024-05-23T13:22:17Z) - Physical formula enhanced multi-task learning for pharmacokinetics prediction [54.13787789006417]
A major challenge for AI-driven drug discovery is the scarcity of high-quality data.
We develop a formula enhanced mul-ti-task learning (PEMAL) method that predicts four key parameters of pharmacokinetics simultaneously.
Our experiments reveal that PEMAL significantly lowers the data demand, compared to typical Graph Neural Networks.
arXiv Detail & Related papers (2024-04-16T07:42:55Z) - PGraphDTA: Improving Drug Target Interaction Prediction using Protein
Language Models and Contact Maps [4.590060921188914]
Key aspect of drug discovery involves identifying novel drug-target (DT) interactions.
Protein-ligand interactions exhibit a continuum of binding strengths, known as binding affinity.
We propose novel enhancements to enhance their performance.
arXiv Detail & Related papers (2023-10-06T05:00:25Z) - MCPI: Integrating Multimodal Data for Enhanced Prediction of Compound
Protein Interactions [15.5883647480458]
The identification of compound-protein interactions (CPI) plays a critical role in drug screening, drug repurposing, and combination therapy studies.
The effectiveness of CPI prediction relies heavily on the features extracted from both compounds and target proteins.
This study proposed a novel model named MCPI, which is designed to improve the prediction performance of CPI.
arXiv Detail & Related papers (2023-06-15T07:20:26Z) - ResDTA: Predicting Drug-Target Binding Affinity Using Residual Skip
Connections [0.0]
We present a deep learning-based methodology for predicting DT binding affinities using just sequencing information from both targets and drugs.
The proposed model achieves the best Concordance Index (CI) performance in one of the largest benchmark datasets.
arXiv Detail & Related papers (2023-03-20T20:27:11Z) - Drug Synergistic Combinations Predictions via Large-Scale Pre-Training
and Graph Structure Learning [82.93806087715507]
Drug combination therapy is a well-established strategy for disease treatment with better effectiveness and less safety degradation.
Deep learning models have emerged as an efficient way to discover synergistic combinations.
Our framework achieves state-of-the-art results in comparison with other deep learning-based methods.
arXiv Detail & Related papers (2023-01-14T15:07:43Z) - SSM-DTA: Breaking the Barriers of Data Scarcity in Drug-Target Affinity
Prediction [127.43571146741984]
Drug-Target Affinity (DTA) is of vital importance in early-stage drug discovery.
wet experiments remain the most reliable method, but they are time-consuming and resource-intensive.
Existing methods have primarily focused on developing techniques based on the available DTA data, without adequately addressing the data scarcity issue.
We present the SSM-DTA framework, which incorporates three simple yet highly effective strategies.
arXiv Detail & Related papers (2022-06-20T14:53:25Z) - DrugOOD: Out-of-Distribution (OOD) Dataset Curator and Benchmark for
AI-aided Drug Discovery -- A Focus on Affinity Prediction Problems with Noise
Annotations [90.27736364704108]
We present DrugOOD, a systematic OOD dataset curator and benchmark for AI-aided drug discovery.
DrugOOD comes with an open-source Python package that fully automates benchmarking processes.
We focus on one of the most crucial problems in AIDD: drug target binding affinity prediction.
arXiv Detail & Related papers (2022-01-24T12:32:48Z) - GEFA: Early Fusion Approach in Drug-Target Affinity Prediction [28.695523040015164]
We propose a novel graph-in-graph neural network with attention mechanism to address the changes in target representation because of the binding effects.
A drug is modeled as a graph of atoms, which then serves as a node in a larger graph of residues-drug complex.
We also use pre-trained protein representation powered by the recent effort of learning contextualized protein representation.
arXiv Detail & Related papers (2020-09-25T11:54:15Z) - Learning-based Computer-aided Prescription Model for Parkinson's
Disease: A Data-driven Perspective [61.70045118068213]
We build a dataset by collecting symptoms of PD patients, and their prescription drug provided by neurologists.
Then, we build a novel computer-aided prescription model by learning the relation between observed symptoms and prescription drug.
For the new coming patients, we could recommend (predict) suitable prescription drug on their observed symptoms by our prescription model.
arXiv Detail & Related papers (2020-07-31T14:34:35Z)
This list is automatically generated from the titles and abstracts of the papers in this site.
This site does not guarantee the quality of this site (including all information) and is not responsible for any consequences.